Genotype-independent association between vitamin D deficiency and polycystic ovarian syndrome in Lahore, Pakistan. by Lone, NM et al.
1Scientific RepoRtS |         (2020) 10:2290  | https://doi.org/10.1038/s41598-020-59228-4
www.nature.com/scientificreports
Genotype-independent association 
between vitamin D deficiency and 
polycystic ovarian syndrome in 
Lahore, pakistan
nasira M. Lone1,2*, Saba Riaz1,3, Amna Z. eusaph4, charles A. Mein5, eva L. Wozniak5, 
theodoros Xenakis5, Zhenqiang Wu6, Sidra Younis2,7, David A. Jolliffe2, Kashaf Junaid8 & 
Adrian R. Martineau2
Both vitamin D deficiency and single nucleotide polymorphisms (SNPs) in the gene encoding the 
vitamin D receptor (VDR) have been widely reported to associate with susceptibility to polycystic 
ovarian syndrome (PCOS). A case-control study was conducted to study the influence of vitamin 
D status and genotpye for 24 SNPs in four genes in the vitamin D pathway (VDR, DBP, CYP27B1, 
CYP24A1) on PCOS. Statistical analyses were conducted to identify phenotypic and genotypic factors 
associated with risk of pcoS and to test for interactions between genotype and vitamin D status. pcoS 
was independently associated with lower age, higher body mass index, lower waist-hip ratio, vitamin D 
deficiency (serum 25-hydroxyvitamin D concentration <10 ng/mL), lack of outdoor exercise, increased 
fasting glucose and a family history of PCOS in at least one first degree relative. No statistically 
significant association was observed between the genotype of any SNP investigated and risk of PCOS, 
either as a main effect or in interaction with vitamin D status. We report a strong and independent 
association between vitamin D deficiency and risk of PCOS in Pakistan, that was not modified by 
genetic variation in the vitamin D pathway.
Polycystic ovary syndrome (PCOS) is the most common reproductive, endocrine and metabolic disorder in 
women of reproductive age1. Globally, the prevalence of PCOS ranges from 4 to 21%, as defined using NIH 1990 
and Rotterdam 2003 criteria2. Epidemiological data from Pakistan are scarce, but the prevalence of PCOS has 
been reported to be particularly high among women of South Asian ethnic origin3,4.
PCOS is thought to arise as a result of the interplay between genetic and environmental factors5. A growing 
body of literature indicates that vitamin D deficiency may be a risk factor: meta-analyses of observational studies 
reveal independent associations between PCOS and low serum concentrations of 25-hydroxyvitamin D (25[OH]
D, the major circulating vitamin D metabolite) as well as single nucleotide polymorphisms [SNPs] in the gene 
encoding the vitamin D receptor (VDR)6–11. However, data relating to vitamin D status among women with 
PCOS in Pakistan are lacking. Moreover, studies in the field have not yet tested for main effects of SNPs in the 
genes encoding the 1-alpha hydroxylase enzyme CYP27B1 (which converts 25[OH]D to its active metabolite 
1,25-dihydroxy vitamin D) or the vitamin D 24-hydroxylase enzyme CYP24A1 (which converts 25[OH]D to its 
major inactive catabolite 24R,25-dihydroxy vitamin D). Neither have they tested for interactions between SNPs 
in the vitamin D pathway and vitamin D status in influencing the risk of PCOS.
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We have previously demonstrated that genetic variation in the vitamin D pathway can modify the influence of 
vitamin D deficiency and supplementation on clinical phenotype in the context of tuberculosis12–14. We, therefore, 
conducted a case control study in Lahore, Pakistan, to determine whether vitamin D deficiency and SNPs in four 
vitamin D pathway genes might influence the risk of PCOS either as main effects or in interaction with each other.
Results
participant characteristics. A total of 235 PCOS cases and 235 healthy controls were recruited to the study 
between April 2016 and April 2018. Characteristics of cases and controls are presented in Table 1. The mean age 
of cases vs. controls was 25.2 vs 29.7 years, respectively, and the majority (96.8%) of participants were of Punjabi 
ethnic origin. Married and single women were equally represented in both groups. Students were over-repre-
sented, and employed women were under-represented, in cases vs controls, but the proportion of participants at 
different educational levels did not differ between groups. As anticipated, acne, hair loss, hirsutism, menstrual 
cycle abnormalities, and pelvic ultrasound scan abnormalities were all more common among cases vs controls. 
The mean body mass index was higher among cases vs controls, but the mean waist-to-hip ratio was lower. 
Mean serum concentrations of fasting glucose and luteinizing hormone were higher in cases vs controls, but no 
difference was seen for mean serum concentration of the follicle-stimulating hormone. As anticipated LH/FSH 
ratio was higher in cases vs controls. Mean serum 25(OH)D concentration was lower in cases vs controls (17.4 vs 
21.7 ng/ml, respectively; P < 0.001).
Association between phenotypic features and risk of pcoS. Table 2 presents the results of univari-
able and multivariable analyses testing for associations between participant characteristics captured by the study 
questionnaire or found at physical examination and susceptibility to PCOS. PCOS was independently associated 
with lower age (adjusted odds ratio [aOR] per additional year of age, 0.86; 95% CI 0.81 to 0.93), higher body mass 
index (aOR per additional kg/m2, 1.26; 95% CI 1.15 to 1.37), lower waist-hip ratio (aOR per additional unit, 0.88; 
Cases 
(n=235)
Controls 
(n=235)
Mean difference 
(95% CI)
Odds ratio (95% 
CI) P
Mean age, years (s.d.) 25.2 (4.8) 29.7 (6.8) 4.5 (3.4, 5.6) — <0.001
Ethnic origin
Punjabi 222 (94.4%) 233 (99.1%) — Ref
Others 13 (5.5%) 2 (0.8%) — 6.82 (1.52, 30.57) 0.01
Marital status
Married 121 (51.5%) 120 (51.1%) — Ref
Single 114 (48.5%) 115 (48.9%) — 1.02 (0.71, 1.46) 0.93
Monthly household income, Pakistani 
Rupees
<25,000 49 (16.6%) 68 (28.9%) — Ref
25,000-100,000 175 (74.5%) 154 (65.5%) — 1.57 (1.03, 2.41) 0.04
>100,000 11 (4.7%) 13 (5.5%) — 1.18 (0.49, 2.84) 0.72
Occupation
Student 96 (40.8%) 54 (22.9%) — Ref
Unemployed 108 (45.9%) 112 (47.6%) — 0.54 (0.35,0.83) 0.005
Employed 31 (13.2%) 69 (29.4%) — 0.25 (0.14, 0.43) <0.001
Education
Illiterate 40 (17%) 34 (14.4%) — Ref
Intermediate 80 (34%) 89 (37.9%) — 0.76 (0.44, 1.32) 0.34
Graduate 115 (48.9%) 112 (47.6%) — 0.87 (0.51, 1.47) 0.61
Acne
Yes 143 (68.8%) 2 (0.01%) —
No 92 (39.1%) 233 (99.1%) 0.01 (0.00, 0.02) <0.001
Hairloss
Yes 177 (75.3%) 28 (11.9%) —
No 58 (24.6%) 207 (88.1%) 0.04 (0.03, 0.07) <0.001
Hirsutism
Yes 193 (82.1%) 0 (0%) —
No 42 (17.9%) 235 (100%) 1 <0.001
Menstrual cycle
Abnormala 210 (89.4%) 0 (0%) —
Normal 25 (10.6%) 235 (100%) - 1 <0.001
Abnormal pelvic ultrasound
Positive 168 (71.5%) 0 (0%) — — —
negative 67 (28.5%) 235 (100%) — 1 <0.001
Mean body mass index, kg/m2 (s.d.) 26.7 (5.2) 24.2 (4.3) −2.4 (−3.3, −1.6) — <0.001
Mean waist-to-hip ratio percentage(s.d.) 80.6 (5.8) 82.7 (3.3) 2.2 (1.3,3.0) <0.001
Mean fasting glucose, mg/dL (s.d.) 103.2 (21.3) 86.1 (7.7) −17.5 (−20.3, −14.8) — <0.001
Mean luteinizing hormone 
concentration (LH), IU/L (s.d.) 10.9 (8.0) 5.9 (3.0) −5.0 (−6.1,-3.9) — <0.001
Mean follicle-stimulating hormone 
concentration (FSH), IU/L (s.d.) 5.5 (2.9) 5.4 (2.0) −0.1 (−0.5, 0.4) — 0.75
Mean LH/FSH ratio (s.d) 3.1 (5.0) 1.2 (1.0) −1.9 (−2.5, −1.2) — <0.001
Mean serum 25(OH)D, ng/ml (s.d.) 17.4 (16.2) 21.7 (7.9) 4.3 (1.9, 6.6) — <0.001
Table 1. Characteristics of cases and controls. a, Abnormal menstrual cycle in Cases: amenorrhea: [28 (11.9%), 
menorrhagia: 18 (7.6%), oligomenorrhea: 164 (69.7%)].
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95% CI 0.82 to 0.95), vitamin D deficiency (serum 25(OH)D <25 ng/ml, aOR 24.81; 95% CI 6.16 to 99.84), lack 
of outdoor exercise (aOR 13.47; 95% CI 6.26 to 28.97), increased fasting glucose (aOR per 1 mg/dL increase, 1.12; 
95% CI 1.09 to 1.17) and a family history of PCOS in at least one first degree relative (aOR 2.75; 95% CI 1.12 to 
6.78). The following features were not found to associate with susceptibility to PCOS: monthly household income, 
or self-reported consumption of sugary/fast foods, chicken, eggs, milk or red meat.
Association between vitamin D pathway genotype and risk of polycystic ovarian syndrome. 
Table 3 presents results of univariable and multivariable analyses testing for associations between SNPs in the 
genes encoding the vitamin D receptor (VDR), the vitamin D 1-alpha hydroxylase enzyme (CYP27B1), the vita-
min D 24-hydroxylase enzyme (CYP24A1) and the vitamin D binding protein (DBP) and risk of PCOS. No 
statistically significant association was observed between the genotype of any polymorphism investigated and 
risk of PCOS.
Association between vitamin D deficiency and host genotype, stratified by vitamin D status. 
We next proceeded to investigate whether genetic variation in VDR, CYP24A1, CYP27B1 and DBP modified 
the association between vitamin D deficiency and risk of PCOS reported above. P values for interaction for these 
sub-group analyses are presented in Table 3: these revealed no evidence to support the hypothesis that polymor-
phisms in the vitamin D pathway modify the effect of vitamin D deficiency on risk of PCOS.
Haplotype analysis. We also performed haplotype analysis to assess the cumulative impact of all SNPs on 
risk of PCOS. The Clark method15 was used to define haplotypes for SNPs showing significant linkage disequi-
librium (R2 > 0.80) in the relevant 1000 genomes reference set ([PJL], Punjabi from Lahore, Pakistan). Two SNPs 
in VDR showed linkage disequilibrium with R2 > 0.80: rs11568820 and rs7976091. Univariate regression analysis 
for haplotypes TT, TC and CC showed no significant association with the odds of PCOS. Further analysis was 
performed by adjusting these haplotypes for the phenotypic risk factors for PCOS identified above (age, BMI, 
WHR, vitamin D status, outdoor physical exercise and fasting glucose). No statistically significant associations 
with risk of PCOS were identified (Table 4).
N
Proportion of 
cases
Proportion of 
controls
Univariable analysis Multivariable analysis
Unadjusted OR 
(95% CI) P
Adjusted odds 
ratio (95% CI)a P
Age, years 470 — — 0.87 (0.84, 0.90) <0.001 0.86 (0.81, 0.93) <0.001
BMI, kg/m2 470 — — 1.12 (1.07, 1.1) <0.001 1.26 (1.15, 1.37) <0.001
Waist: hip ratio, % 470 — — 0.91 (0.86, 0.94) <0.001 0.88 (0.82, 0.95) <0.001
Deseasonalized serum 
25(OH)D, ng/ml
≥10 381 149/235 (63.4%) 232/235 (98.7%) — — Ref —
<10 89 86/235 (36.6%) 3/235 (1.3%) 44.63 (13.86, 143.72) <0.001 24.8 (6.16, 99.84) <0.001
Monthly household 
income, Pakistani Rupees
<25,000 117 49/235 (16.6%) 68/235 (28.9%) — — — —
25,000-100,000 329 175/235 (74.5%) 154/235 (65.5%) 1.57 (1.03, 2.41) 0.04 — —
>100,000 24 11/235 (4.7%) 13/235 (5.5%) 1.18 (0.49, 2.84) 0.72 — —
Family history of PCOSb
No 393 184/235 (78.3%) 209/235 (88.9%) — — — —
Yes 77 51/235 (21.7%) 26/235 (11.0%) 2.23 (1.34, 3.72) <0.001 2.75 (1.12, 6.78) 0.03
Outdoor exercise
Yes 284 76/235 (32.3%) 208/235 (88.5%) — — — —
No 186 159/235 (67.7%) 27/235 (11.5%) 16.12 (9.92, 26.18) <0.001 13.47 (6.26, 28.97) <0.001
Fasting glucose, mg/dL 470 — — 1.11 (1.09, 1.14) <0.001 1.12 (1.09, 1.17) <0.001
Sugary / fast food 
consumption
No 286 129/235 (54.9%) 157/235 (66.8%) — — — —
Yes 184 106/235 (45.1%) 78/235 (33.2%) 1.65 (1.14, 2.40) <0.001 1.13 (0.56, 2.29) 0.72
Chicken consumption
Daily/weekly 96 51/235 (21.7%) 45/235 (19.1%) — — — —
Less often 374 184/235 (78.3%) 190/235 (80.9%) 1.20 (0.75, 1.83) 0.49 — —
Egg consumption
Daily/weekly 347 180/235 (76.6%) 167/235 (71.1%) — — — —
Less often 123 55/235 (23.4%) 68/235 (28.9%) 0.75 (0.49, 1.13) 0.17 — —
Milk consumption
Daily/weekly 268 89/235 (37.9%) 179/235 (76.2%) — — — —
Less often 202 146/235 (62.1%) 56/235 (23.8%) 5.24 (3.51, 7.81) <0.001 1.45 (0.72, 2.92) 0.29
Red meat consumption
Daily/weekly 133 61/235 (26.0%) 72/235 (30.6%) — — — —
Less often 337 174/235 (74.0 %) 163/235 (69.4 %) 1.25 (0.84, 1.89) 0.26 — —
Table 2. Determinants of PCOS risk from study questionnaire and physical examination. Abbreviations: BMI, 
body mass index; 25(OH)D 25-hydroxyvitamin D. a, Adjusted for age, BMI, waist-to-hip ratio, deseasonalized 
25(OH)D <10 ng/ml vs ≥10 ng/ml, outdoor exercise, fasting glucose, sugary/fast food consumption and milk 
consumption. b, PCOS in at least one first-degree relative.
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Gene SNP Genotype
Proportion with 
PCOS
Unadjusted OR 
(95% CI)
P for unadjusted 
OR
Adjusted odds ratio 
(95% CI)a
P for main 
effect
P for interaction 
between genotype 
and vitamin D statusb
VDR rs1544410
CC 143/284 (50.4%) 0.93 (0.68, 1.26) 0.64 0.78 (0.46, 1.33) 0.37 0.99
TC 77/152 (50.7%)
TT 11/26 (42.3%)
VDR rs2228570
GG 56/110 (50.9%) 0.97 (0.75, 1.25) 0.75 0.93 (0.59, 1.47) 0.76 0.93
GA 109/218 (50%)
AA 63/127 (49.6%)
VDR rs7970314
AA 89/173 (51.5%) 0.99 (0.77, 1.27) 0.92 0.72 (0.46, 1.15) 0.17 0.99
GA 97/200 (48.5%)
GG 46/89 (51.6%)
VDR rs4334089
GG 15/31 (48.3%) 1.03 (90.77, 1.39) 0.82 0.92 (0.56, 1.52) 0.74 0.30
GA 73/148 (49.3%)
AA 138/275 (50.2%)
VDR rs731236
AA 89/193 (46.1%) 1.20 (0.92, 1.56) 0.17 1.66 (1.02, 2.69) 0.04 0.78
GA 106/204 (52%)
GG 37/68 (54.4%)
VDR rs7976091
CC 119/229 (52%) 1.02 (0.78, 1.34) 0.85 0.94 (0.58, 1.53) 0.81 0.98
TC 78/167 (46.7%)
TT 32/55 (58.2%)
VDR rs2853559
GG 135/277 (48.7%) 1.15 (0.85, 1.54) 0.36 1.28 (0.71, 2.30) 0.41 0.99
GA 81/157 (51.6%)
AA 17/30 (56.6%)
VDR rs7975232
AA 17/33 (52%) 0.78 (0.58, 1.05) 0.10 1.00 (0.57, 1.75) >0.99 0.92
CA 90/162 (55.6%)
CC 116/255 (45.5%)
VDR rs10783219
AA 27/49 (55.1%) 0.97 (90.74, 1.29) 0.85 1.06 (0.65, 1.73) 0.87 0.56
TA 92/198 (46.4%)
TT 101/203 (49.7%)
VDR rs2238136
CC 111/222 (50%) 1.06 (0.81, 1.39) 0.64 0.92 (0.56, 1.52) 0.75 0.98
TC 79/173 (45.6%)
TT 32/55 (58.2%)
VDR rs4516035
TT 35/68 (51.5%) 1.07 (0.82, 1.39) 0.61 1.08 (0.68, 1.69) 0.74 0.53
TC 95/203 (46.8%)
CC 97/185 (52.4%)
VDR rs11568820
CC 25/43 (58.1%) 1.01 (0.77, 1.34) 0.92 1.28 (0.80, 2.15) 0.31 0.69
TC 68/152 (44.7%)
TT 137/266 (51.5%)
DBP rs2070741
TT 129/251 (51.4%) 0.92 (0.68, 1.22) 0.56 1.08 (0.65, 1.80) 0.76 0.66
GT 83/172 (48.3%)
GG 17/35 (48.6%)
DBP rs7041
AA 46/112 (41.1%) 1.14 (0.88, 1.47) 0.31 1.20 (0.77, 1.86) 0.41 0.054
CA 128/225 (57%)
CC 61/126 (48.4%)
DBP rs4588
GG 19/43 (44.2%) 0.96 (0.73, 1.27) 0.77 0.92 (0.57, 1.48) 0.72 0.99
TG 98/179 (55%)
TT 117/241 (49%)
DBP rs16846876
AA 152/300 (51%) 0.96 (0.70, 1.33) 0.83 0.74 (0.41, 1.33) 0.32 0.99
TA 66/139 (47.5%)
TT 11/20 (55%)
DBP rs2298849
AA 178/356 (50%) 1.11 (0.74, 1.64) 0.61 0.94 (0.45, 1.96) 0.86 0.98
GA 46/97 (47.4%)
GG 6/7 (86%)
DBP rs12512631
TT 78/157 (49.6%) 0.97 (0.76, 1.24) 0.82 0.96 (0.62, 1.49) 0.85 0.93
TC 105/201 (52.2%)
CC 49/103 (47.6%)
Continued
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Discussion
We report findings from one of the largest and most detailed studies conducted to date to investigate the influ-
ence of vitamin D deficiency and genetic variation in the vitamin D pathway on susceptibility to PCOS – and the 
first such study to be conducted in Pakistan. Uniquely, in addition to investigating SNPs in VDR and DBP, we 
also explored the influence of variants in CYP24A1 (the gene encoding the major enzymes of 25(OH)D catabo-
lism) and CYP27B1 (the gene encoding the enzyme responsible for converting 25[OH]D to its active metabolite 
1,25[OH]2D) on risk of disease. Our major findings were that lower vitamin D status was independently asso-
ciated with susceptibility to PCOS, but that genetic variation in VDR, DBP, CYP24A1, and CYP27B1 was not. 
Moreover, we found no evidence of any interaction between serum 25(OH)D levels and genetic variation in the 
vitamin D pathway on disease risk.
Our finding that vitamin D deficiency associates independently with PCOS risk in women in Pakistan is con-
sistent with reports from other settings including the Netherlands10, Iran16, Egypt17 and the USA18, as well as with 
findings from a meta-analysis including these and other studies19, showing that mean 25(OH)D level was lower 
in women with PCOS than controls. The high prevalence of vitamin D deficiency seen among participants in the 
current study is in keeping with our previous study in Lahore showing a high prevalence of vitamin D deficiency 
among women of reproductive age20. These and other studies reporting high rates of vitamin D deficiency in 
other groups21, highlight that vitamin D deficiency is a major public health problem in Pakistan22. The adjusted 
odds ratio for the association between vitamin D deficiency at the pre-specified 25(OH)D cut-off of 10 ng/ml 
was higher than has been reported elsewhere; this primarily reflects the very low prevalence of 25(OH)D values 
<10 ng/ml among controls in the current study. Exploratory analyses investigating 25(OH)D cut-offs of 15 ng/ml 
(aOR 3.41, 95% CI 1.77 to 6.57), 20 ng/ml (aOR 1.79, 95% CI 0.96 to 3.37), or analyzing 25(OH)D as a continu-
ous variable (aOR 0.98, 95% CI 0.96 to 1.01) showed consistent inverse associations between 25(OH)D level and 
PCOS risk. Our findings with regard to other factors associated with PCOS, such as higher BMI, reduced physical 
exercise, higher fasting glucose levels and positive family history are also in keeping with the literature22–25.
In contrast to these positive findings, the lack of association seen between polymorphisms in VDR in our 
study contrasts with findings of a recent meta-analysis reporting that the VDR ApaI (rs7975232) polymorphism 
associated with susceptibility to PCOS in Asian populations (aOR for allelic model, C vs A, 1.19; 95% CI 1.07 to 
1.34)6. The lack of association seen for SNPs in DBP is consistent with findings of both the other studies that have 
investigated polymorphisms in this gene26,27.
Our study has several strengths. Cases comprised a broad range of PCOS phenotypes, including obese and 
lean, fertile and infertile, and those with and without hyper-androgenic characteristics. We collected detailed 
information on potential confounders of the association between vitamin D status and PCOS risk, minimizing 
the potential for residual/unmeasured confounding to explain our findings. We also investigated SNPs in a wider 
range of vitamin D pathway genes than previously investigated, and applied a stringent correction for multiple 
testing. By deseasonalizing 25(OH)D data, we were able to calculate individuals average 25(OH)D level through-
out the year, which represents their vitamin D status more effectively than a season-specific ‘snapshot’ provided 
by a single unadjusted reading28.
Gene SNP Genotype
Proportion with 
PCOS
Unadjusted OR 
(95% CI)
P for unadjusted 
OR
Adjusted odds ratio 
(95% CI)a
P for main 
effect
P for interaction 
between genotype 
and vitamin D statusb
CYP24A1 rs6013897
TT 107/213 (50.2%) 1.06 (0.81, 1.39) 0.65 1.42 (0.86, 2.36) 0.17 0.72
TA 96/194 (49.5%)
AA 31/56 (55.4%)
CYP24A1 rs2762939
GG 101/214 (47.2%) 1.14 (0.88, 1.49) 0.32 1.37 (0.84, 2.25) 0.19 0.63
GC 104/196 (53.1%)
CC 29/56 (52%)
CYP24A1 rs2248137
CC 94/185 (51%) 0.91 (90.70, 1.18) 0.48 0.93 (0.45, 1.96) 0.39 0.98
GC 101/201 (50.3%)
GG 34/75 (45.3%)
CYP24A1 rs2762934
GG 40/74 (54.1%) 0.96 (0.75, 1.25) 0.79 0.93 (0.58, 1.49) 0.71 0.82
GA 97/199 (49.7%)
AA 96/189 (51%)
CYP27B1 rs4646536
AA 1/1 (100%) 0.72 (0.32, 1.60) 0.42 1.70 (0.34, 8.56) 0.52 0.99
GA 12/22 (54.5%)
GG 216/436 (49.5%)
CYP27B1 rs4646537
TT 105/216 (48.6%) 1.06 (0.80, 1.39) 0.69 0.98 (0.61, 1.56) 0.92 0.98
GT 97/185 (52.4%)
GG 24/49 (48.9%)
Table 3. Genotypic determinants of PCOS risk. Abbreviations: PCOS, polycystic ovarian syndrome; SNP, single 
nucleotide polymorphism. a, Adjusted for age, body mass index, waist-to-hip ratio, deseasonalized 25(OH)D 
<10 ng/ml vs ≥10 ng/ml, outdoor exercise and fasting glucose. b, P value for interaction between genotype and 
25(OH)D <10 ng/ml vs ≥10 ng/ml is presented.
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Our study also has some limitations. Due to the case-control design, reverse causality and/or confounding 
cannot be excluded as explanations for the associations observed. Although large by comparison with others in 
the field, our power to detect modest genetic effects, and gene-environment interactions, was limited. 25(OH)D 
was measured by ELISA rather than with Liquid Chromatography Tandem Mass Spectrometry, which is the gold 
standard methodology; however, this should not have introduced bias, since the same assay was used to measure 
vitamin D status in cases and controls. Moreover, the assay we used detects both 25(OH)D2 and 25(OH)D3.
conclusion
In conclusion, this large case-control study—the first of its kind to be conducted in Pakistan—reports that low 
vitamin D status associates independently with increased susceptibility to PCOS. However, no statistically sig-
nificant association between polymorphisms in vitamin D pathway genes and risk of PCOS was demonstrated.
Methods
Study design. We conducted a case control study. Cases were patients aged 14 to 49 years diagnosed with 
PCOS and recruited from out-patient clinics at the Jinnah Hospital and the Lady Willingdon Hospital, Lahore. 
A total of 235 women were selected according to Rotterdam criteria, 200329. Patients with thyroid and adrenal 
diseases and androgen-secreting tumours were excluded. 235 healthy controls were selected from the Citi lab 
and Research centre, Lahore, on the basis of having no history of infertility, no evidence of clinical hyperandro-
genism and normal menstrual cycles. Informed consent was taken from all participants who fulfilled eligibility 
criteria. Written informed consent was taken from the parents or guardians of the participants who were under 
18 years of age. Participants completed a detailed questionnaire including details of age, weight, height, socio-
demographic status, dietary habits, physical exercise, sun exposure, androgenic features (acne, hirsutism and 
patchy hair loss), menstrual cycle history, family history of PCOS and fertility details for married participants. 
The study was approved by the ethical committee of the University of Punjab (Ref No: Bioethic 125Pu, 13.10.17) 
and by the ethical review board of Citi lab and Research Centre, Lahore (Ref # 26-17/ERB/CLRC/27th/Dated 
28-07-2016). All the methods were performed following the relevant guidelines and regulations approved by the 
ethical committee.
5 mL of blood was drawn on the 2nd or 3rd day of menstrual cycle30, from a median cubital vein; 2 mL were 
transferred into vials containing EDTA and frozen at −20 °C for subsequent DNA extraction, and 3 mL was added 
to serum vials and sent to the laboratory within two hours of collection, where serum was isolated from clotted 
blood by centrifugation and stored at −20 °C for subsequent determination of 25(OH)D concentration.
Serum 25(OH)D assay. Serum 25(OH) D concentration was determined by ELISA (Calbiotech, EI Cajon 
U.S.A). Calibrators and controls for the assay were run in duplicates. Interassay CV for serum 25(OH)D for our 
samples was 14%. Season-adjusted (deseasonalized) values for 25(OH)D were calculated for each participant 
from their individual standardized 25(OH)D concentration and date of blood sample collection, using a sinusoi-
dal model with values derived from standardized values for all participants as previously described28,31. Vitamin D 
deficiency was defined using a pre-specified 25(OH)D cut-off of 10 ng/ml; this cut-off was selected a priori on the 
basis that it is widely used by Public Health bodies32 and that deficiency at this level has been shown to associate 
most strongly with PCOS11 and other pathologies attributable to vitamin D deficiency33–35.
Genotyping. Genomic DNA was extracted from whole blood and quantified using a nanodrop spectro-
photometer as previously described36. DNA TaqMan allelic probe assays (Applied Biosystems, Foster City, CA, 
USA) were used to genotype polymorphisms in genes encoding: the vitamin D receptor (rs4334089, rs10783219, 
rs4516035, rs11568820 [cdx2], rs7976091, rs731236 [TaqI], rs2228570 [Fok]I, rs1544410 [BsmI], rs7975232 
[ApaI], rs7970314, rs2853559, rs2238136); the 1α-hydroxylase enzyme, CYP27B1 (rs4646536, rs4646537); the 
24-hydroxylase enzyme, CYP2A41 (rs6013897, rs2762939, rs2248137, rs2762934), and the vitamin D binding 
protein, DBP (rs7041, rs4588, rs12512631, rs2070741, rs2298849, rs16846876). Taqman® SNP genotyping assays 
were purchased directly from Life Technologies. Assay IDs are detailed in Supplementary Table 1. One assay 
was a custom design and primer details are shown in Supplementary Table 2. For SNP Genotyping using the 
Fluidigm 192.24 Dynamic Array, genomic DNA concentration was normalised to 50 ng/µL and a sample pre-mix 
was prepared with 2 µL of GTXpress™ Master Mix (2×), 0.2 µL of 20X Fast GT Sample Loading Reagent, 0.2 µL 
of nuclease-free water and 1.6 µL of genomic DNA. A 10X SNP assay mix was prepared by combining 1.0 µL of 
Taqman® SNP Genotyping assay with 2.0 µL of 2X Assay Loading Reagent, 0.2uL of ROX™ (50×) and 1.3 µL 
Haplotype Presence
Proportion with 
PCOs
Unadjusted OR 
(95% CI)
p-value of 
unadjusted OR
Adjusted OR 
(95% CI)a p-value
CC
No 134/256 (52.3%) Ref — —
Yes 90/189 (47.6%) 0.83 (0.57, 1.20) 0.32 0.70 (0.36, 1.38) 0.31
TT
No 117/227 (51.5%) Ref —
Yes 107/218 (49.1%) 0.91 (0.625, 1.31) 0.60 1.08 (0.56, 2.09) 0.81
TC
No 55/95 (57.9%) Ref —
Yes 169/350 (48.3%) 0.68 (0.43, 1.07) 0.09 0.66 (0.29, 1.46) 0.34
Table 4. Haplotype analysis. a, Adjusted for age, body mass index, waist-to-hip ratio, deseasonalized 25(OH)D 
<10 ng/ml vs ≥10 ng/ml, outdoor exercise and fasting glucose.
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of nuclease-free water. 3 µL of sample pre-mix and 3 µL of assay mix into each assay inlet of the 192.24 arrays. 
Pressure fluid was then pipetted into the appropriate wells. The array was then loaded to the Juno™ controller 
with the RX insert and the Fast PCR 192.24 script run to performs thermal cycling. Thermal conditions were 
as follows: Hot start 95 °C for 5 minutes, Touchdown (64 °C-61 °C dropping 1 °C per cycle) 4 cycles at 95 °C for 
15 seconds, 64 °C 45 for seconds, 72 °C for15 seconds, 34 cycles were run at 95 °C for 15 seconds (denaturing) 
followed by 60 °C for 45 seconds (annealing) and 72 °C for 15 seconds (extension). Endpoint fluorescent data were 
collected using the Biomark® Real-Time PCR System, and data were subsequently analysed using the Fluidigm 
SNP Genotyping Analysis software.
Statistical analysis. Statistical analyses were done with Stata IC (version 15.1). Frequencies of alleles and 
genotypes were compared using chi-square tests; all were found to be in Hardy-Weinberg equilibrium. Baseline 
characteristics of cases vs controls were compared using unpaired Student’s t-tests and chi-square tests for contin-
uous and categorical variables, respectively. Chi-square tests were used to test for associations between independ-
ent variables and risk of PCOS in univariate analysis. Binary logistic regression was used for multivariate analysis 
of phenotypic determinants of PCOS risk, with adjustment for factors found to associate with PCOS with P < 0.05 
in the univariate analysis of phenotypic determinants. Binary logistic regression was also used to test for associa-
tion between genotype and risk of PCOS, using an additive model and adjusting for phenotypic factors found to 
associate independently with PCOS risk (age, body mass index, waist-to-hip ratio, deseasonalized 25(OH)D <10 
vs. ≥10 ng/ml, outdoor exercise and fasting glucose). Sub-group analyses were performed to determine whether 
genetic variation in the vitamin D pathway modified effects of vitamin D status on susceptibility to PCOS by 
repeating primary efficacy analysis with the inclusion of a term for the interaction between vitamin D status and 
genotype, using an additive model. Haplotype analysis was performed using the Clark method. Odds ratios are 
presented with 95% confidence intervals and P values. The Benjamini-Hochberg procedure for multiple testing 
correction37 was applied to genetic analyses to control the false discovery rate (FDR) at 5%.
power and sample size. Assuming the risk of vitamin D deficiency (serum 25[OH]D <10 ng/ml) in the 
control arm to be 56%38, we calculated that 235 cases and 235 controls would need to be recruited in order to 
detect an odds ratio for the association between vitamin D deficiency and risk of PCOS of ≥1.86 with 80% power 
and an alpha of 5%.
Data availability
The primary data for this study is available from the corresponding author on direct request.
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